Silence Therapeutics, a biotech company focused on gene-silencing treatments, surged 59% to $6.11 after agreeing to a $1.3 billion takeover by Merck KGaA. Merck will pay $20 per American depositary share, a 130% premium over Silence's recent closing price, valuing the company at about $1.3 billion. The acquisition follows promising phase two data for Silence's key drug divesiran, targeting a rare blood cancer. The deal, approved by Silence's board, is expected to close in early 2027, pending shareholder and regulatory approvals, and will provide Merck with enhanced capabilities in rare disease treatments.
Silence Therapeutics' takeover news is presented here with Pluang's health sector market data as of Oct 19, 2026 22:21 WIB. For readers following health stocks, out of 150 priced US health-sector stocks tradable on Pluang, 73 rose and 70 fell today. Notable movers include RLAY at USD 16.86 with a 3.56% increase, TNGX at USD 22.82 up 3.54%, and ADMA at USD 11.04 rising 3.37%.
Ethereum-based crypto Pepeto is in its final presale stages ahead of a Binance listing, with rapid investor interest driving record presale speed. Pepeto addresses issues Cardano aimed to fix, such as high fees and network congestion, offering zero-f...
The global migraine market is projected to expand at a 6% annual growth rate through 2036, driven by rising migraine prevalence, better diagnosis, and awareness. Innovative treatments beyond traditional CGRP inhibitors, including PACAP-targeted thera...
Miracles, a company specializing in personalized children's books where each child becomes the story's hero, has printed over 100,000 books for more than 45,000 families. The books are printed locally in Germany and delivered within a few days, offer...
Miracles, a personalized children's book maker, has printed more than 100,000 books, serving over 45,000 families. Each book features a unique 3D character of the child, created from a single photo, making the child the hero of the story. Books for U...
Roth Capital increased its price target for Chord Energy to $165 from $145 following strong Q3 2026 operational performance, including production exceeding forecasts and capital spending within budget. The company also executed $205 million in share ...
